Dexmetomidine promotes the activity of breast cancer cells through miR-199a/HIF-1α axis

Abstract

Background Breast cancer, as one of the most common malignant tumors in women, is still a great threat to women all over the world. Dexmetomidine (DMED) is a highly selective α2-adrenergic receptor agonist, which has attracted much attention in recent years. This study aimed to clarify the potential mechanism of DMED in regulating the activity of breast cancer cells. Methods Breast cancer cell lines MCF-7 and MDA-MB-231 were treated with DMED. The levels of miR-199a and HIF-1α mRNA were detected using quantitative real-time polymerase chain reaction (QRT-PCR); the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) and transwell assays were applied to monitor the activity of breast cancer cells; the apoptosis of breast cancer cells was detected using the caspase-3 activity assay and flow cytometry; binding of miR-199a and HIF-1α was assessed using double luciferase reporter gene assay, and western blot was employed to monitor the level of HIF-1α in cells. Results The cytotoxicity and apoptosis of MCF-7 and MDA-MB-231 cells was inhibited by DMED. It also downregulated the expression of miR-199a in breast cancer cells and enhanced the downregulation of miR-199a to promote the activity of breast cancer cells and inhibit apoptosis. Also, miR-199a targeted HIF-1α. Further functional experiments confirmed that DMED promoted the progression of breast cancer through the miR-199a/HIF-1α axis. Conclusions DMED promotes the activity of breast cancer cells through miR-199a/HIF-1αaxis. This can provide some reference for DMED in the clinical treatment of breast cancer.

Breast cancer and neurotransmitters: emerging insights on mechanisms and therapeutic directions

“…Based on in vitro and xenotransplant in vivo assays, Xia et al reported that dexmedetomidine could increase the proliferation, migration, and invasion of breast cancer cells via activation of α2B-adrenoceptor / ERK signaling[45]. Subsequent studies have corroborated this finding and proposed explanatory mechanisms[46][47][48][49], while none have shown a finding of sufficient significance to discourage use of the anesthetic.…”

MYO1B as a prognostic biomarker and a therapeutic target in Arecoline‐associated oral carcinoma

“…In colon cancer, upregulation of MYO1B promoted tumor metastasis by mediating the RhoA/ROCK/FAK signaling pathway, resulting in poor prognosis in patients 44 . Besides, increased expression of MYO1B could also be detected in cervical cancer tissues, 45 which was correlated with high proliferation and invasive ability of cervical cancer cells and unfavorable outcomes 46 . Taken together, overexpression of MYO1B may promote proliferation, metastasis, and invasion in a variety of cancers.…”

“…MYO1B, Myosin 1b. proliferation and invasive ability of cervical cancer cells and unfavorable outcomes 46. Taken together, overexpression of MYO1B may promote proliferation, metastasis, and invasion in a variety of cancers.…”

Anaesthesia and cancer recurrence: the influence of perioperative anaesthetic technique on cancer recurrence after surgery

“…Dexmedetomidine is a centrally acting a2 adrenoreceptor agonist used perioperatively for sedative, analgesic and sympatholytic properties. Although limited clinical studies exist, recent animal model data points towards dexmedetomidine's potential role in promoting cancer recurrence and metastasis, especially after breast cancer surgery [66], possibly related to the presence of a2 adrenoreceptors in breast cancer tissue [67]. Sparse evidence also suggests dexmedetomidine may reduce the degree of immunosuppression during cancer surgery.…”